Guadecitabine SGI-110 and Donor Lymphocyte Infusions (Dli) After Allogeneic Stem Cell Transplantation (Allo Sct) in Very High Risk MDS or AML Patients
Status: Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 24 Nov 2018
Price : $35 *
At a glance
- Drugs Guadecitabine (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- 13 Nov 2018 Planned initiation date changed from 1 Sep 2018 to 1 Nov 2018.
- 31 Aug 2018 Biomarkers information updated
- 31 Jul 2018 Planned primary completion date changed from 1 May 2020 to 1 Sep 2020.